Contrary to the effect of AMD3100 on GAD67 levels in the peri-infarct area, treatment did not change GAD65 levels in AMD-treated mice (0.94 ± 0.13, n = 6) compared to vehicle-treated animals (1.01 ± 0.17, n = 5) subjected to PT (Fig. 6D). This evidence concerns the gene GAD1 and age-related macular degeneration.